{"filings":[{"id":90663,"accession_number":"0001493152-26-015365","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics terminates CFO Alexander Arrow, effective April 30, 2026","event_type":"leadership","confidence":"high","bullets":["CFO Alexander Arrow notified on March 31, 2026 that employment will be terminated.","Termination effective April 30, 2026; no successor or interim CFO announced.","Company common stock (PTIX) and warrants (PTIXW) trade on OTC Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100376,"accession_number":"0001493152-26-008605","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics appoints William Nichols as President; base salary $350k, 40% bonus target, 1% option grant","event_type":"leadership","confidence":"high","bullets":["William (Bill) Nichols, Jr., age 51, appointed President effective Feb 3, 2026.","Prior senior commercial leadership roles at bluebird bio, Dova Pharmaceuticals, and Bristol-Myers Squibb.","Annual base salary $350,000; eligible for annual target bonus of 40% of base salary.","Employment agreement includes option grant equal to ~1.0% of fully diluted share count.","No family relationships or transactions requiring Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100375,"accession_number":"0001493152-26-007800","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","1.02","2.01","3.02","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation","event_type":"other_material","confidence":"high","bullets":["Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.","PTIX returns 100% of Phytanix Bio shares; receives back all PTIX common and preferred stock issued as consideration.","PTIX pays Phytanix Bio $300,000 at closing and $10,000 upon receipt of specified financial information.","Litigation styled Protagenic v. Alterola Biotech et al. dismissed with prejudice.","Mutual releases and indemnification provisions between parties; former Phytanix stockholders resign from PTIX positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100374,"accession_number":"0001493152-26-000263","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026","event_type":"other_material","confidence":"high","bullets":["Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).","Trading on Nasdaq will cease at close of Jan 2, 2026; OTC trading expected to start Jan 5, 2026.","Company has withdrawn its hearing request, making delisting final.","Company intends to evaluate steps to regain compliance and seek relisting on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116703,"accession_number":"0001493152-25-025159","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.","Company also cited for delayed Form 10-Q for quarter ended September 30, 2025 (Rule 5250(c)(1)).","Will request hearing before Nasdaq Hearings Panel; automatic 15-day stay of suspension granted.","Common stock and warrants will continue trading on Nasdaq during automatic stay and any extended stay.","Company expects to file the overdue 10-Q imminently but no assurance Panel will grant relief."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116702,"accession_number":"0001493152-25-020881","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jennifer Chao resigns from Protagenic Therapeutics Board","event_type":"leadership","confidence":"high","bullets":["Jennifer Chao resigned from the Board of Directors on November 3, 2025, effective immediately.","No disagreements were reported between Ms. Chao and the Company.","Her departure reduces the board size; no replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116701,"accession_number":"0001493152-25-020444","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages","event_type":"litigation","confidence":"high","bullets":["Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.","Seeks rescission of May 15, 2025 Share Exchange Agreement acquiring Phytanix Bio.","Alternatively seeks damages and an order compelling delivery of audited financials.","Lawsuit challenges the entire transaction; no settlement or resolution disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133146,"accession_number":"0001493152-25-013851","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K/A","filed_at":"2025-09-17T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Protagenic Therapeutics updates auditor consent for Phytanix acquisition; no material news","event_type":"other","confidence":"low","bullets":["Company files Exhibit 23.1 with consent of GreenGrowth CPAs Inc.","Financial statements and pro forma data from prior filing remain unchanged.","Acquisition of Phytanix Bio was previously reported on May 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133145,"accession_number":"0001641172-25-025737","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K/A","filed_at":"2025-08-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings","event_type":"other_material","confidence":"high","bullets":["Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).","On Aug 8, Board approved restructuring: suspended preclinical programs, terminated CEO Barrett Evans and COO Colin Stott.","Restructuring expected to cut annual operating expenses by ~$8M; focus on Phase 2 trial of PT00114.","Changed auditor from MaloneBailey to GreenGrowth CPAs; fiscal year changed from Dec 31 to March 31, effective Aug 7, 2025.","Historical Phytanix loss from ops $2.6M for year ended Mar 31, 2025; cash used in ops $1.8M; ~$1M ATM capacity remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133150,"accession_number":"0001641172-25-025274","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01","4.01","7.01","9.01"],"status":"ready","headline":"Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete","event_type":"regulatory","confidence":"high","bullets":["Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.","Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.","Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.","Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133149,"accession_number":"0001641172-25-023588","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.05","5.02","5.03","8.01"],"status":"ready","headline":"Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated","event_type":"other_material","confidence":"high","bullets":["Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.","Annual operating expenses to be reduced by ~$8 million when fully implemented; one-time charges not yet estimable.","CEO Barrett Evans and COO Colin Stott terminated effective immediately; both remain on the Board.","All preclinical programs (PHYX-001 through PHYX-005) paused; company pursuing partnerships or out-licensing.","Fiscal year-end changed from Dec 31 to Mar 31; transition report on Form 10-QT for Apr 1–Jun 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133148,"accession_number":"0001641172-25-021552","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics granted Japan patent for modified stilbenoid epilepsy drug candidates","event_type":"regulatory","confidence":"high","bullets":["Japanese Patent Office granted Patent JP 7714571B on July 18, 2025, covering modified stilbenoid compounds.","Patent runs until March 31, 2041, providing exclusivity for treating epilepsy and seizures.","Builds on previously granted UK patent GB2609814 for same program.","Japanese pharma market worth >$85B; global epilepsy drug market expected to reach $18.7B by 2034.","Company expects to expand patent protection to other territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133147,"accession_number":"0001641172-25-020802","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics appoints Timothy R. Wright as Class II director","event_type":"leadership","confidence":"high","bullets":["Timothy R. Wright appointed to board effective July 18, 2025 as Class II director, term expires at 2026 annual meeting.","Board determined Wright is independent under Nasdaq rules; board now has three independent directors.","Wright is Executive Chairman of Isosceles (since 2019) and President/CEO of BIORG, INC. (since 2023).","He also serves on the board of Agenus Inc. (since 2006) and previously held executive roles at Covidien/Medtronic and Teva.","Wright will receive standard non-employee director compensation as described in the January 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149754,"accession_number":"0001641172-25-016979","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Protagenic Therapeutics declares rights offering at $0.01 per share to preserve ownership after Phytanix acquisition","event_type":"other_material","confidence":"high","bullets":["Board authorized distribution of one Right per common share held as of July 7, 2025 record date.","Each Right entitles holder to purchase 4.57 common shares at $0.01 per share, subject to stockholder approval.","Rights become exercisable only after stockholder meeting approves Phytanix acquisition and share issuance; exercisable for up to 6 months.","Rights initially trade with Common Stock, become separable after approval; Rights Agreement with Equiniti Trust Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149753,"accession_number":"0001641172-25-011878","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises","event_type":"other_material","confidence":"high","bullets":["Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.","Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.","Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.","Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149752,"accession_number":"0001641172-25-011633","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Protagenic Therapeutics exchanges 459,420 warrants for 367,544 shares at 0.8 ratio","event_type":"other_material","confidence":"high","bullets":["Warrant Exchange Agreement with unaffiliated holder to cancel 459,420 warrants for 367,544 common shares.","Exchange relies on Section 3(a)(9) exemption; shares issued without restrictive legends.","Transaction to be completed within six months of May 20, 2025.","Net reduction of 91,876 potential shares outstanding compared to exercise of warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149751,"accession_number":"0001641172-25-011387","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025","Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders","Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer","Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing","Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}